| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Human papillomavirus and survival of patients with oropharyngeal cancer.
|
N Engl J Med
|
2010
|
22.74
|
|
2
|
Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.
|
N Engl J Med
|
2013
|
19.87
|
|
3
|
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing.
|
Nature
|
2012
|
14.33
|
|
4
|
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.
|
Nature
|
2012
|
9.89
|
|
5
|
The origin and evolution of mutations in acute myeloid leukemia.
|
Cell
|
2012
|
9.66
|
|
6
|
Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus.
|
Nature
|
2005
|
8.55
|
|
7
|
Whole-genome analysis informs breast cancer response to aromatase inhibition.
|
Nature
|
2012
|
8.03
|
|
8
|
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas.
|
Nat Genet
|
2012
|
7.61
|
|
9
|
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.
|
N Engl J Med
|
2014
|
5.37
|
|
10
|
A novel retinoblastoma therapy from genomic and epigenetic analyses.
|
Nature
|
2012
|
5.02
|
|
11
|
Novel mutations target distinct subgroups of medulloblastoma.
|
Nature
|
2012
|
4.82
|
|
12
|
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts.
|
Cell Rep
|
2013
|
3.85
|
|
13
|
Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas.
|
Nat Genet
|
2013
|
3.51
|
|
14
|
The genomic landscape of hypodiploid acute lymphoblastic leukemia.
|
Nat Genet
|
2013
|
3.43
|
|
15
|
Genome sequence of Theileria parva, a bovine pathogen that transforms lymphocytes.
|
Science
|
2005
|
2.71
|
|
16
|
Association of age at diagnosis and genetic mutations in patients with neuroblastoma.
|
JAMA
|
2012
|
2.49
|
|
17
|
The Princeton Protein Orthology Database (P-POD): a comparative genomics analysis tool for biologists.
|
PLoS One
|
2007
|
1.83
|
|
18
|
Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer.
|
Cancer
|
2011
|
1.63
|
|
19
|
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.
|
Invest New Drugs
|
2007
|
1.53
|
|
20
|
Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: a prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventory-Head and Neck Module.
|
Cancer
|
2014
|
1.53
|
|
21
|
Genetic variations in the regulator of G-protein signaling genes are associated with survival in late-stage non-small cell lung cancer.
|
PLoS One
|
2011
|
1.51
|
|
22
|
Predicting cellular growth from gene expression signatures.
|
PLoS Comput Biol
|
2009
|
1.50
|
|
23
|
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
|
J Clin Oncol
|
2012
|
1.37
|
|
24
|
Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience.
|
Int J Radiat Oncol Biol Phys
|
2011
|
1.37
|
|
25
|
Measuring the symptom burden of lung cancer: the validity and utility of the lung cancer module of the M. D. Anderson Symptom Inventory.
|
Oncologist
|
2011
|
1.30
|
|
26
|
Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy.
|
J Natl Cancer Inst
|
2011
|
1.27
|
|
27
|
Safety of early discharge for low-risk patients with febrile neutropenia: a multicenter randomized controlled trial.
|
J Clin Oncol
|
2011
|
1.26
|
|
28
|
Effects of N-acetyl transferase 1 and 2 polymorphisms on bladder cancer risk in Caucasians.
|
Mutat Res
|
2004
|
1.20
|
|
29
|
MSIsensor: microsatellite instability detection using paired tumor-normal sequence data.
|
Bioinformatics
|
2013
|
1.17
|
|
30
|
Opposing effects of emphysema, hay fever, and select genetic variants on lung cancer risk.
|
Am J Epidemiol
|
2005
|
1.17
|
|
31
|
Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia.
|
J Clin Oncol
|
2008
|
1.14
|
|
32
|
Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer.
|
PLoS One
|
2010
|
1.12
|
|
33
|
Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer.
|
Cancer
|
2011
|
1.12
|
|
34
|
Levels of symptom burden during chemotherapy for advanced lung cancer: differences between public hospitals and a tertiary cancer center.
|
J Clin Oncol
|
2011
|
1.11
|
|
35
|
Analysis of the transcriptome of the protozoan Theileria parva using MPSS reveals that the majority of genes are transcriptionally active in the schizont stage.
|
Nucleic Acids Res
|
2005
|
1.09
|
|
36
|
Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma.
|
Thyroid
|
2013
|
1.07
|
|
37
|
Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy.
|
Pharmacogenet Genomics
|
2008
|
1.05
|
|
38
|
Telomere length in peripheral blood leukocytes and lung cancer risk: a large case-control study in Caucasians.
|
Cancer Res
|
2014
|
1.04
|
|
39
|
Genetic variants in cell cycle control pathway confer susceptibility to lung cancer.
|
Clin Cancer Res
|
2007
|
1.04
|
|
40
|
Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer.
|
Cancer
|
2010
|
1.03
|
|
41
|
PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.
|
Lung Cancer
|
2010
|
1.02
|
|
42
|
Yeast metabolic and signaling genes are required for heat-shock survival and have little overlap with the heat-induced genes.
|
Proc Natl Acad Sci U S A
|
2013
|
1.01
|
|
43
|
Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer.
|
Clin Cancer Res
|
2006
|
1.01
|
|
44
|
Value of p16INK4a and RASSF1A promoter hypermethylation in prognosis of patients with resectable non-small cell lung cancer.
|
Clin Cancer Res
|
2004
|
1.00
|
|
45
|
Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.
|
Clin Cancer Res
|
2004
|
0.98
|
|
46
|
Expression of telomere-associated genes as prognostic markers for overall survival in patients with non-small cell lung cancer.
|
Clin Cancer Res
|
2006
|
0.97
|
|
47
|
High symptom burden prior to radiation therapy for head and neck cancer: a patient-reported outcomes study.
|
Head Neck
|
2012
|
0.96
|
|
48
|
RB1 gene inactivation by chromothripsis in human retinoblastoma.
|
Oncotarget
|
2014
|
0.96
|
|
49
|
Genome-wide association study of genetic predictors of overall survival for non-small cell lung cancer in never smokers.
|
Cancer Res
|
2013
|
0.96
|
|
50
|
Polymorphisms of STK15 (Aurora-A) gene and lung cancer risk in Caucasians.
|
Carcinogenesis
|
2006
|
0.91
|
|
51
|
Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
|
Int J Radiat Oncol Biol Phys
|
2004
|
0.91
|
|
52
|
Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer.
|
Carcinogenesis
|
2011
|
0.91
|
|
53
|
Systematic evaluation of apoptotic pathway gene polymorphisms and lung cancer risk.
|
Carcinogenesis
|
2012
|
0.90
|
|
54
|
Deficient G2-M and S checkpoints are associated with increased lung cancer risk: a case-control analysis.
|
Cancer Epidemiol Biomarkers Prev
|
2007
|
0.89
|
|
55
|
Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC).
|
Invest New Drugs
|
2010
|
0.87
|
|
56
|
ATM sequence variants associate with susceptibility to non-small cell lung cancer.
|
Int J Cancer
|
2007
|
0.86
|
|
57
|
The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
|
Cancer
|
2002
|
0.85
|
|
58
|
Clinical and pharmacokinetic study of TNP-470, an angiogenesis inhibitor, in combination with paclitaxel and carboplatin in patients with solid tumors.
|
Cancer Chemother Pharmacol
|
2004
|
0.84
|
|
59
|
Common genetic variants in cell cycle pathway are associated with survival in stage III-IV non-small-cell lung cancer.
|
Carcinogenesis
|
2011
|
0.79
|
|
60
|
TGFβ1 Polymorphisms Predict Distant Metastasis-Free Survival in Patients with Inoperable Non-Small-Cell Lung Cancer after Definitive Radiotherapy.
|
PLoS One
|
2013
|
0.78
|
|
61
|
Socioeconomic status is associated with depressive severity among patients with advanced non-small-cell lung cancer: treatment setting and minority status do not make a difference.
|
J Thorac Oncol
|
2014
|
0.77
|
|
62
|
Prognostic value of patient-reported symptom interference in patients with late-stage lung cancer.
|
Qual Life Res
|
2013
|
0.76
|
|
63
|
High mutagen sensitivity in peripheral blood lymphocytes predicts poor overall and disease-specific survival in patients with stage III non-small cell lung cancer treated with radiotherapy and chemotherapy.
|
Clin Cancer Res
|
2005
|
0.76
|
|
64
|
Pharmacogenetics in esophageal cancer.
|
Semin Oncol
|
2005
|
0.76
|
|
65
|
Initial medical attention on patients with early-stage non-small cell lung cancer.
|
PLoS One
|
2012
|
0.75
|
|
66
|
[Distinguishing second primary tumors from lung metastasis in patients with postoperative non-small cell lung cancer by microsatellite analysis].
|
Zhonghua Jie He He Hu Xi Za Zhi
|
2007
|
0.75
|